Philips Respironics has recently released a Field Safety Notification for a number of positive airway pressure (PAP) devices used for treatment of sleep apnoea and respiratory failure. According to the manufacturer, the polyester-based polyurethane foam used in their devices may degrade into particles and volatile gas products, which the user may inhale. This may result in potential health risks for the user, including local airway irritation.
This webinar offers the opportunity to assess the real and potential acute and chronic risk for the patient due to physical or chemical injuries on the one hand, against the acute and chronic risk of cessation of treatment of sleep apnoea or respiratory failure on the other, and discusses the current realised recommendations for respiratory, sleep and critical care medicine professionals and patients regarding the Philips recall notice.
- To give an overview of the impact of Philips Respironics’ Field Safety Notification on patients with sleep apnoea and respiratory failure currently under treatment with the affected devices.
- To discuss recommendations for respiratory, sleep and critical care medicine professionals as illustrated in the ERS Statement, towards a stepwise and individualised patient approach regarding their treatment with the potential affected devices.
- To discuss patients’ perspectives, answering questions on their treatment and potential risks, and attempting to provide them with solutions.
One introductory presentation followed by a panel discussion, with Prof. Anita Simonds and Prof. Winfried Randerath as moderators.
- ERS Statement regarding Philips Respironics’ Field Safety Notification
- Panel discussion presenting the impact of this notification on the treatment of sleep apnoea and respiratory failure patients from children to adults, followed by questions posed by ELF representative to panellists.
Following the webinar, participants will be able to:
- Identify and evaluate the impact of affected devices on SDB patients as well as the strategy for solutions and prevention, based on ERS recommendations.
- From a patient’s perspective, gain knowledge regarding their treatment.
An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.
What is a webinar?
The webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting.
This webinar comprises a 40-minute lecture followed by a 20-minute question-and-answer session. During the webinar you will be asked to share your opinion on issues related to the topic using interactive polls.
All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.
More information will be communicated in due course.
- Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact firstname.lastname@example.org.
- Check Central European Summer Time.
- To achieve the best quality, we recommend stopping all other programmes and avoiding downloading anything from the internet during your connection to the lecture.
- Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.
Diseases / methods
- Sleep and breathing disorders
- Respiratory critical care
- Paediatric respiratory diseases
- Respiratory, Sleep and Critical care physicians
- Sleep technicians
- Respiratory nurses